Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics (Nasdaq: NTLA) will report topline clinical data from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema on April 27, 2026. This is described as the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate.
The company will host a webcast at 8:00 a.m. ET on April 27, 2026 to discuss the topline results; a replay will be available for approximately 90 days.
Loading...
Loading translation...
Positive
World's first Phase 3 readout for an in vivo CRISPR candidate
Topline data release scheduled April 27, 2026 with an 8:00 a.m. ET webcast
Negative
None.
News Market Reaction – NTLA
-4.33%1.8x vol
118 alerts
-4.33%Session close to close
+10.8%Peak Tracked
-11.4%Trough Tracked
$1.79BMarket Cap
1.8xRel. Volume
In the Apr 27 session, NTLA declined 4.33%, reflecting a moderate negative market reaction.
Argus tracked a peak move of +10.8% during that session.
Argus tracked a trough of -11.4% from its starting point during tracking.
Our momentum scanner triggered 118 alerts that day, indicating very high trading interest and price volatility.
Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
This announcement sets a firm date—April 27, 2026—for topline results from the global Phase 3 HAELO ...
Analysis
This announcement sets a firm date—April 27, 2026—for topline results from the global Phase 3 HAELO trial of lonvo-z in hereditary angioedema, following earlier Phase 1/2 data showing deep and durable attack reductions. Prior clinical updates across lonvo-z and nex-z have typically produced modest but directionally positive moves. Key factors to watch include consistency with the earlier 96% attack reduction, safety outcomes, and any guidance on regulatory timelines and commercialization plans.
Key Figures
Phase 3 readout date:April 27, 2026Phase 1/2 HAE cohort size:32 patients (n=32)HAE attack reduction:96% reduction+5 more
8 metrics
Phase 3 readout dateApril 27, 2026Global Phase 3 HAELO topline for lonvo-z in HAE
Phase 1/2 HAE cohort size32 patients (n=32)Pooled lonvo-z Phase 1/2 HAE cohort at 50 mg
HAE attack reduction96% reductionMean reduction in HAE attacks vs baseline in pooled cohort
Attack-free & LTP-free rate31/32 patients (97%)Lonvo-z HAE patients at data cutoff in pooled analysis
Plasma kallikrein reduction89% at month 24Lonvo-z Phase 1/2 pooled HAE data at 24 months
Presented pooled Phase 1/2 lonvo-z HAE data with high attack-free and LTP-free rates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent clinical trial announcements have generally led to positive price moves, though one notably positive lonvo-z data update saw a negative reaction, indicating occasional divergence between strong data and market response.
Recent Company History
Over the past six months, NTLA has released multiple clinical trial updates across its CRISPR portfolio. For lonvo-z in HAE, pooled Phase 1/2 data showed deep and durable attack reductions, while earlier communications foreshadowed Phase 3 HAELO topline timing. For nex-z in ATTR, FDA lifts of clinical holds for MAGNITUDE and MAGNITUDE-2 and longer-term Phase 1 data in ATTR-CM highlighted robust TTR lowering and clinical stability. Today’s Phase 3 HAELO topline date marks the next major step for lonvo-z after these earlier-phase results.
Key Terms
phase 3, in vivo, crispr, gene editing, +2 more
6 terms
phase 3medical
"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
in vivomedical
"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"
In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.
crisprmedical
"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"
CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.
gene editingmedical
"World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate"
Gene editing is a set of laboratory techniques that change the DNA inside living cells to add, remove, or alter specific genes, like using precise 'cut-and-paste' tools to edit an instruction manual for a living organism. It matters to investors because successful edits can produce new therapies, improve agricultural products, or create commercial advantages; progress, safety, regulatory approvals, and patent control all affect a company’s value and risk profile.
topline clinical datamedical
"announced the company will report topline clinical data from its global Phase 3 HAELO"
Topline clinical data are the initial, high-level results released after a medical study that summarize whether the trial met its main goals and flag any major safety issues. Investors treat them like a headline summary of a longer report: they quickly indicate whether a drug or treatment is likely to move forward with regulators and reach the market, but they don’t include the full details that can change the longer-term story.
hereditary angioedemamedical
"clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE)"
A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.
World’s first Phase 3 readout for an in vivo CRISPR gene editing candidate
Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026
CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.
To join the webcast, please visit the Events page of the Investors & Media section on Intellia’s website at intelliatx.com. A replay of the webcast will be available for approximately 90 days.
About Intellia Therapeutics Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. jason.fredette@intelliatx.com
When will Intellia (NTLA) report topline HAELO Phase 3 data for lonvoguran ziclumeran?
Intellia will report topline Phase 3 HAELO data on April 27, 2026. According to the company, a webcast to discuss the data will begin at 8:00 a.m. ET and a replay will be available for roughly 90 days.
What is significant about the HAELO Phase 3 readout for NTLA's lonvo-z?
The HAELO readout is described as the world's first Phase 3 for an in vivo CRISPR gene editing candidate. According to the company, this marks a milestone in clinical development for in vivo CRISPR therapeutics.
How can investors listen to Intellia's April 27, 2026 webcast about NTLA trial results?
Investors can join the webcast via the Events page in the Investors & Media section on Intellia's website. According to the company, the live event starts at 8:00 a.m. ET and a replay will be posted for about 90 days.
What drug is being evaluated in Intellia's Phase 3 HAELO trial (NTLA)?
The HAELO trial is evaluating lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. According to the company, topline clinical data from the global Phase 3 trial will be reported on April 27, 2026.
Will a replay be available after Intellia's April 27 NTLA webcast and for how long?
Yes, a replay will be available for approximately 90 days following the webcast. According to the company, the replay will be accessible via the Events page in the Investors & Media section of its website.
